| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Precision Neuroscience | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $1.84M | -- | 5 | Not available | -- | -- | $466.59M | Series D | 9/11/2026 | $287.5M | $1.04B | $7.20 | Undisclosed Investors | ||||
 | Chai Discovery | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $100.13K | -- | 1 | -- | Not available | -- | -- | $620.17M | Series C | 7/14/2026 | $400M | $3.8B | $178.05 | Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite, Scribble Ventures | ||||
 | Xaira Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1B | Series A | 4/23/2024 | $500M | $2.65B | $2.50 | ARCH Venture Partners, Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy, Byers Capital, Rsquared, SV Angel, AIM13, Breyer Capital, Deviation Capital, Foresite Labs, JSL Health Capital, Longwood Fund, Sahsen Ventures, WRF Capital | ||||
 | Twin Health | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $100.00K | -- | 1 | -- | Not available | -- | -- | $363.98M | Series F | 6/29/2026 | $59.01M | $1.4B | $19.86 | Undisclosed Investors | ||||
 | Freenome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.35B | Series F | 2/15/2024 | $263.96M | $2.05B | $7.40 | Roche, Andreessen Horowitz, BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | ||||
 | Orca Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $541.19M | Series F | 1/9/2026 | $136.35M | $2.4B | $54.99 | Lightspeed Venture Partners | ||||
 | Element Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.5B | Series D-1 | 7/11/2024 | $138.5M | $1.05B | $7.84 | Wellington Management, Samsung Electronics, Fidelity, Foresite Capital, T. Rowe Price Associates, Venrock | ||||
 | Generate Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $812.92M | Series C | 1/21/2025 | $399.4M | $2.22B | $11.85 | Amgen, Nvidia, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis | ||||
 | ArsenalBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $2.44B | Series C | 9/4/2024 | $327.5M | $1.66B | $18.58 | ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVIDIA, Luma Group, T. Rowe Price Associates, Rock Springs Capital, Parker Institute for Cancer Immunotherapy, SoftBank, Bristol-Myers Squibb, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, Hitachi Ventures | ||||
 | Asimov | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $241.8M | Series B | 1/5/2023 | $175M | $1.24B | $92.68 | CPP Investments, Fidelity, KDT, Casdin Capital, Pillar, Andreessen Horowitz, Horizons Ventures | ||||
 | Kriya Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $940.5M | Series D | 9/10/2025 | $320.82M | $1.67B | $10.34 | Patient Square Capital, Premji Invest, Peter Thiel, Narya Capital, The T1D Fund | ||||
 | Mammoth Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $379.07M | Series D-3 | 12/2/2025 | $15M | $1.35B | $13.45 | Undisclosed Investors | ||||
 | Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.77M | Series B-1 | 6/8/2022 | $50M | $1.46B | $45.70 | Bristol Myers Squibb | ||||
 | Alloy Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.24M | Series E-1 | 4/15/2026 | $30M | $1B | $26.17 | 8VC, JIC Venture Growth Investments, Echo Capital, Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, Ulysses Diversified Holdings | ||||
 | Alzheon | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $268.07M | Series F | 8/26/2026 | $78.8M | $1.34B | $62.71 | Undisclosed Investors | ||||
 | Insitro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.26B | Series C | 3/15/2021 | $400M | $2.57B | $18.29 | CPP Investments, Andreessen Horowitz, T. Rowe Price, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, Temasek, Softbank | ||||
 | Kailera Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $959.96M | Series B | 10/14/2025 | $603.18M | $1.4B | $14.00 | Bain Capital, Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, QIA, Royalty Pharma, Surveyor Capital, T. Rowe Price, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Sirona Capital | ||||
 | Synthego | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $415.07M | Series E | 2/17/2022 | $144.17M | $1.3B | $10.78 | Perceptive Advisors, SoftBank, Declaration Partners, Laurion Capital Management, Logos Capital, GigaFund, Chimera Abu Dhabi, Wellington Management, RA Capital Management, Moore Strategic Ventures | ||||
 | Kardigan | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $607.17M | Series B-1 | 10/14/2025 | $80.78M | $1.6B | $21.37 | Fidelity, T. Rowe Price, ARCH Venture Partners, Sequoia Heritage | ||||
 | Medable | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $530.96M | Series D | 10/26/2021 | $304.88M | $2.1B | $9.67 | Blackstone Growth, Tiger Global, GSR Ventures, Sapphire Ventures, WTI | ||||
 | Eikon Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.16B | Series D | 2/14/2025 | $350.7M | $1.85B | $5.84 | Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, T. Rowe Price, UC Investments | ||||
 | Formation Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $744.65K | -- | 2 | Not available | -- | -- | $3.38B | Series D | 6/26/2024 | $372M | $1.48B | $8.18 | Andreessen Horowitz, Sanofi, Sequoia Capital, Thrive Capital, Emerson Collective, Lachy Groom, SV Angel Growth, FPV Ventures | ||||
 | Prime Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $315.76M | Series B | 7/13/2021 | $200M | $1.23B | $4.38 | ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, Public Sector Pension Investment Board, Redmile Group, Samsara BioCapital, T. Rowe Price | ||||
 | Ginkgo Bioworks | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $785.53M | Series E | 5/28/2020 | $360M | $4.89B | $150.19 | T. Rowe Price, Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Reshape Holdings, Viking Global Investors, Illumina | ||||